Avient Co. (NYSE:AVNT – Get Rating) – Oppenheimer dropped their Q4 2022 earnings estimates for shares of Avient in a report released on Tuesday, January 24th. Oppenheimer analyst K. Owen now expects that the company will post earnings of $0.20 per share for the quarter, down from their previous estimate of $0.29. Oppenheimer currently has a "Market Perform" rating on the stock. The consensus estimate for Avient's current full-year earnings is $2.90 per share. Oppenheimer also issued estimates for Avient's Q1 2023 earnings at $0.59 EPS, Q2 2023 earnings at $0.57 EPS and FY2024 earnings at $2.54 EPS.

AVNT has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Avient from $40.00 to $35.00 in a report on Thursday, November 3rd. Morgan Stanley dropped their target price on shares of Avient from $37.00 to $34.00 and set an "equal weight" rating for the company in a research report on Monday, November 7th. Robert W. Baird boosted their target price on shares of Avient from $35.00 to $44.00 in a research report on Tuesday, December 20th. Wells Fargo & Company boosted their target price on shares of Avient from $33.00 to $41.00 and gave the company an "overweight" rating in a research report on Monday, January 9th. Finally, TheStreet cut shares of Avient from a "b-" rating to a "c+" rating in a research report on Monday, October 24th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $45.14.

Avient Stock Performance

Avient (NYSE:AVNT – Get Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.61 by ($0.02). The business had revenue of $823.30 million during the quarter, compared to the consensus estimate of $850.82 million. Avient had a net margin of 4.08% and a return on equity of 16.11%. The business's revenue for the quarter was up .6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.70 EPS.

Hedge Funds Weigh In On Avient

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James & Associates boosted its stake in Avient by 22.7% during the first quarter. Raymond James & Associates now owns 29,947 shares of the company's stock worth $1,437,000 after acquiring an additional 5,546 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Avient by 2.2% in the first quarter. American Century Companies Inc. now owns 10,341 shares of the company's stock valued at $496,000 after acquiring an additional 221 shares during the period. US Bancorp DE boosted its position in shares of Avient by 3.5% in the first quarter. US Bancorp DE now owns 8,862 shares of the company's stock valued at $425,000 after acquiring an additional 297 shares during the period. Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Avient in the first quarter valued at approximately $110,000. Finally, Bank of Montreal Can lifted its position in Avient by 9.4% during the first quarter. Bank of Montreal Can now owns 15,146 shares of the company's stock valued at $748,000 after purchasing an additional 1,296 shares during the last quarter. 93.81% of the stock is currently owned by institutional investors and hedge funds.

Avient Company Profile

(Get Rating)

Avient Corporation provides specialized formulator, services, and sustainable material solutions in the United States, Canada, Mexico, Europe, South America, and Asia. It operates through three segments: Color, Additives and Inks; Specialty Engineered Materials; and Distribution. The Color, Additives and Inks segment offers specialized color and additive concentrates in solid and liquid form for thermoplastics; dispersions for thermosets; and specialty inks.

Read More

• Get a free copy of the StockNews.com research report on Avient (AVNT)
• Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
• Is The Bottom In For Cyber-Security Stocks?
• Union Pacific, Norfolk Southern Pull into Buying Zone
• Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
• How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

Receive News & Ratings for Avient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avient and related companies with MarketBeat.com's FREE daily email newsletter.